1414578-42-9

Basic information

• Product Name: 5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethane sulfonate
• Synonyms: 5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethane sulfonate
• CAS NO: 1414578-42-9
• Molecular Weight: 321.28
• Mol File: 1414578-42-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethane sulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethane sulfonate(1414578-42-9)
• EPA Substance Registry System: 5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethane sulfonate(1414578-42-9)

Safety Data

• Hazardous Substances Data: 1414578-42-9(Hazardous Substances Data)

Upstream product

• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 100-63-0 phenylhydrazine 
• 934397-98-5 5-amino-4-methyl-1-phenyl-1H-pyrazol-3(2H)-one 

Downstream Products

• 1610374-09-8 4-methyl-3-(6-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-amine 
• 1610373-40-4 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(6-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea 
• 1610374-12-3 5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1,3-dimethylpyridin-2(1H)-one 
• 1610373-91-5 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea 

Relevant articles and documents

PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES

The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and f

N-PYRROLIDINYL, N'-PYRAZOLYL- UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.